Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
about
Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutationsEvaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic reviewA Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, RussiaPyrosequencing for rapid detection of tuberculosis resistance in clinical isolates and sputum samples from re-treatment pulmonary tuberculosis patientsMolecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from China.Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand.Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays.Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter StudyMicroevolution of extensively drug-resistant tuberculosis in Russia.Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing.Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China.Triplex real-time PCR melting curve analysis for detecting Mycobacterium tuberculosis mutations associated with resistance to second-line drugs in a single reaction.Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains.Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China.Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of Mycobacterium tuberculosis.Molecular biology of drug resistance in Mycobacterium tuberculosisFighting an old disease with modern tools: characteristics and molecular detection methods of drug-resistant Mycobacterium tuberculosis.Antibiotic resistance mechanisms in M. tuberculosis: an update.A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study.In vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin.Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China.Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a Molecular Analysis of Historical Isolates.Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen tMolecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide capreomycin antibiotics in Korea
P2860
Q28397752-6BAFC472-1501-4AC8-B894-6478CDBAC743Q28481845-E86F4D97-4B3C-41D9-847F-6041728E0486Q28554618-EECC9243-3EBA-48C8-B12D-D89427ED9E2CQ33612729-82E78220-E03A-4729-BC2D-C8ABA904B8CFQ33622808-76F9A482-91E3-482D-8B21-EE39C173EE6CQ33826477-FA289028-25DB-4235-9205-64AE352185C6Q34738488-1468C71F-A9D0-403F-82FC-33D13B990F04Q35693044-A4E990CB-9D62-4DC0-8EA5-23C39357F7CDQ35864738-24B0257E-4BA4-45C8-89B5-9EE54FE362DEQ36022970-27ECFED7-D6EB-4D95-AE67-E127F62665FEQ36118776-24703B71-1681-468A-A9A5-74953A6C0DDAQ36762984-A6FE9485-776B-40A3-8885-F9013F027288Q36933151-21B72797-9F0D-42B4-B0A4-8D43FBA49CF2Q37036485-31914840-C3B0-4A92-949A-EEE9986AE088Q37612943-2DA27F39-6B24-4FA9-95DD-50FB44739FECQ37713793-B1ED86DF-4826-4F66-AA76-C3D3BF7B0B5FQ38062402-939A560E-7915-439E-BE7C-2A8A4629E57BQ38545953-58DF9307-8FB2-4446-8239-767EEFBFE828Q38830420-F217018D-359E-41AC-9F5C-97E9C2A750B1Q47659186-69239FAE-10BE-4F4E-8398-FEAA984991E5Q50134142-EC55EF66-238D-4BC5-8DE8-2BCA53F006FEQ51718512-0E1965FF-8985-4EFC-A33C-EF480BA29ABDQ52668649-ABFF5279-E4D1-49C2-885C-0C7A681E97C9Q57212971-1B6E8918-C7D4-4320-99E9-9E5DF699103AQ57224073-25B0A7EE-F1F4-459F-A563-A8631F5B978D
P2860
Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Comparison of clinical isolate ...... in Mycobacterium tuberculosis.
@en
Comparison of clinical isolate ...... in Mycobacterium tuberculosis.
@nl
type
label
Comparison of clinical isolate ...... in Mycobacterium tuberculosis.
@en
Comparison of clinical isolate ...... in Mycobacterium tuberculosis.
@nl
prefLabel
Comparison of clinical isolate ...... in Mycobacterium tuberculosis.
@en
Comparison of clinical isolate ...... in Mycobacterium tuberculosis.
@nl
P2093
P2860
P356
P1476
Comparison of clinical isolate ...... in Mycobacterium tuberculosis.
@en
P2093
Anna Engström
Jim Werngren
Nasrin Perskvist
Pontus Juréen
Sven E Hoffner
P2860
P304
P356
10.1093/JAC/DKR109
P407
P577
2011-03-21T00:00:00Z